Erectile dysfunction (ED) is inconvenient enough on its own. The last thing you want is a pile-on of other inconveniences, like having to go to a doctor’s office for a diagnosis and prescription — and ...

The company that once focused on discreet issues like hair loss and ED is now leaning into full-spectrum wellness — from nutrient testing to longevity. Dudum says diagnostic capabilities will ...

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...

Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million users fueling growth. Despite the Novo Nordisk partnership loss, Hims ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...